• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BetterInvesting™ Magazine Update on The Walt Disney Co. (NYSE: DIS)

    6/5/25 1:58:00 PM ET
    $AMGN
    $DIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Get the next $AMGN alert in real time by email

    TROY, Mich., June 5, 2025 /PRNewswire/ -- Based on recent updated information, the Securities Review Committee of BetterInvesting Magazine has revised its previous decision pertaining to Stride Inc.'s announced selection as the "Stock to Study" for the August 2025 issue. The Walt Disney has been chosen instead as the "Stock to Study" for August.

    The Walt Disney Co.'s recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine consider Disney (NYSE:DIS) as worthy of further study and has named the company its "Stock to Study" for the August 2025 issue for investors' informational and educational use.

    The fundamental data is eye-opening; investors can view Disney's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors Corp., at: https://ssg.betterinvesting.org/trial/ssgplus/?studyid=16958122.

    A full report on Disney will appear in the August 2025 issue of BetterInvesting Magazine. 

    The same issue of BetterInvesting Magazine will also include a fundamental review of Amgen Inc.  (AMGN: NASDAQ), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. 

    Committee members are Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip Keating, CFA; Walter J. Kirchberger, CFA; Anne Nichols, CFA; and Dan Rutter, CFA.

    Doron P. Levin, an editor of the magazine, serves as the committee's chairperson.

    Securities mentioned are for study and presented for educational purposes only. They are not to be considered as endorsed or recommended for purchase by NAIC/BetterInvesting. Investors should conduct their own review and analysis of any company of interest using the Stock Selection Guide before making an investment decision.

    About BetterInvesting:

    BetterInvesting™, a national 501(c)(3) nonprofit, investment education organization, has been empowering everyday Americans since 1951. Also known as the National Association of Investors™ (NAIC®), we have helped more than 5 million people from all walks of life learn how to improve their financial future. BetterInvesting provides unbiased, in-depth investing education and powerful online stock analysis tools to create successful lifelong investors. BetterInvesting staff, along with a dedicated community of volunteers across America, teach the organization's principles and time-tested methodology to individuals and investment clubs. For more information about BetterInvesting, please visit www.betterinvesting.org

    Follow us on LinkedIn, Instagram and Facebook.

    Contact: 877-275-6242

    Cision View original content:https://www.prnewswire.com/news-releases/betterinvesting-magazine-update-on-the-walt-disney-co-nyse-dis-302474596.html

    SOURCE NAIC-BetterInvesting

    Get the next $AMGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMGN
    $DIS

    CompanyDatePrice TargetRatingAnalyst
    Amgen Inc.
    $AMGN
    9/3/2025Mkt Perform
    Raymond James
    Walt Disney Company
    $DIS
    7/29/2025$130.00 → $138.00Overweight
    Analyst
    Walt Disney Company
    $DIS
    7/16/2025$120.00 → $138.00Buy
    UBS
    Walt Disney Company
    $DIS
    6/30/2025$144.00Hold → Buy
    Jefferies
    Walt Disney Company
    $DIS
    6/3/2025$135.00 → $140.00Buy
    Rosenblatt
    Amgen Inc.
    $AMGN
    5/20/2025$288.00Neutral
    Guggenheim
    Amgen Inc.
    $AMGN
    4/22/2025$305.00Neutral
    Cantor Fitzgerald
    Walt Disney Company
    $DIS
    4/21/2025$112.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $AMGN
    $DIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

    THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE, ASTRO, ORBIT or VOYAGER). This analys

    9/9/25 12:12:26 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

    THOUSAND OAKS, Calif. and TOKYO, Sept. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE, ASTRO, ORBIT or VOYAGER). This analysis focuse

    9/8/25 8:04:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE

    THOUSAND OAKS, Calif., Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m. ET on September 9, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found

    9/4/25 4:01:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $DIS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcdonald Calvin bought $999,994 worth of Disney Common Stock (11,756 units at $85.06), increasing direct ownership by 111% to 22,313 units (SEC Form 4)

    4 - Walt Disney Co (0001744489) (Issuer)

    8/9/24 4:33:36 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Gorman James P bought $2,120,628 worth of Disney Common Stock (20,000 units at $106.03), increasing direct ownership by 4,283% to 20,467 units (SEC Form 4)

    4 - Walt Disney Co (0001744489) (Issuer)

    5/9/24 7:06:37 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Chang Amy bought $99,918 worth of Disney Common Stock (1,078 units at $92.69), increasing direct ownership by 21% to 6,216 units (SEC Form 4)

    4 - Walt Disney Co (0001744489) (Issuer)

    12/8/23 4:59:03 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AMGN
    $DIS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Amgen Inc.

    SCHEDULE 13G/A - AMGEN INC (0000318154) (Subject)

    9/8/25 11:06:01 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3ASR filed by Walt Disney Company

    S-3ASR - Walt Disney Co (0001744489) (Filer)

    8/28/25 4:12:16 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 10-Q filed by Walt Disney Company

    10-Q - Walt Disney Co (0001744489) (Filer)

    8/6/25 6:44:22 AM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AMGN
    $DIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AMGN
    $DIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AMGN
    $DIS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Sr. EVP and Chief HR Officer Coleman Sonia L sold $233,701 worth of Disney Common Stock (1,971 units at $118.57), closing all direct ownership in the company (SEC Form 4)

    4 - Walt Disney Co (0001744489) (Issuer)

    8/25/25 6:01:47 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SVP & CCO Grygiel Nancy A. sold $376,280 worth of shares (1,267 units at $296.99), decreasing direct ownership by 15% to 7,209 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    8/22/25 7:21:55 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ishrak Omar was granted 121 shares, increasing direct ownership by 2% to 6,242 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    8/12/25 7:27:28 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on Amgen

    Raymond James resumed coverage of Amgen with a rating of Mkt Perform

    9/3/25 8:26:50 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst reiterated coverage on Walt Disney with a new price target

    Analyst reiterated coverage of Walt Disney with a rating of Overweight and set a new price target of $138.00 from $130.00 previously

    7/29/25 9:43:44 AM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    UBS reiterated coverage on Walt Disney with a new price target

    UBS reiterated coverage of Walt Disney with a rating of Buy and set a new price target of $138.00 from $120.00 previously

    7/16/25 9:25:02 AM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for PAVBLU issued to AMGEN INC

    Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:

    8/26/24 5:53:38 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    8/21/24 12:12:47 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $DIS
    Leadership Updates

    Live Leadership Updates

    View All

    ESPN to Acquire NFL Network and Other Media Assets From the NFL in Exchange for a 10% Equity Stake in ESPN

    Fans to Benefit from Increased Consumer Choice, Greater Accessibility, and Expanded High-Quality Programming and Content Offerings Through ESPN ESPN to Own and Operate NFL Network, With Plans to Fully Integrate it into ESPN's Upcoming Direct-to-Consumer Service NFL's RedZone Channel to Join The Walt Disney Company's Linear Networks Distribution Portfolio; and ESPN Fantasy Football to Combine with NFL Fantasy, Creating an Enhanced Offering and Broader Reach to Meet Global Demand NFL to Also License Games, NFL RedZone, NFL Films programming as well as Content and Other Rights to ESPN ESPN, a subsidiary of The Walt Disney Company (NYSE:DIS), and the National Football League (NFL) today

    8/5/25 8:00:00 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer

    NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi

    7/21/25 7:00:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Walt Disney Company Launches Inaugural, Company-Wide "Disney Week of Wishes" Campaign to Celebrate World Wish Day With Make-A-Wish

    As the world's largest wish granter for Make-A-Wish, Disney grants a wish every hour of every day all year long Today, The Walt Disney Company (NYSE:DIS) kicks off a weeklong company-wide campaign to celebrate its 45-year relationship with Make-A-Wish® by launching the first ever "Disney Week of Wishes." During this unprecedented week, Disney is honoring World Wish Day on April 29 by sharing unique wishes selected by Make-A-Wish kids that only Disney can make come true. This includes a wish-granting moment on American Idol, a Princess-themed ball for nearly 50 families at Disney World, and making one girl's wish of meeting a star of the Marvel Cinematic Universe come true. The unique power

    4/28/25 10:00:00 AM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AMGN
    $DIS
    Financials

    Live finance-specific insights

    View All

    Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

    THOUSAND OAKS, Calif. and TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE:4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE, ASTRO, ORBIT or VOYAGER). This analys

    9/9/25 12:12:26 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

    THOUSAND OAKS, Calif. and TOKYO, Sept. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in adults and adolescents with moderate to severe atopic dermatitis (AD). The ongoing ASCEND study, which includes approximately 2,600 patients, is designed to evaluate the long-term safety and efficacy of rocatinlimab (150 mg and 300 mg) administered every four or eight weeks in individuals who completed a previous ROCKET program trial (IGNITE, HORIZON, SHUTTLE, ASTRO, ORBIT or VOYAGER). This analysis focuse

    9/8/25 8:04:00 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS

    Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs  THOUSAND OAKS, Calif., Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to invest more than $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand Oaks, California. The center is designed to bring together researchers, engineers and scientists across disciplines to enhance collaboration and accelerate the discovery of next-generation therapeutics for patients with the most serious diseases. The building will feature advanced automation and digital capabilities, empowering scientists with the tools and environment needed

    9/2/25 9:01:00 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMGN
    $DIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    2/13/24 4:58:51 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Walt Disney Company (Amendment)

    SC 13G/A - Walt Disney Co (0001744489) (Subject)

    2/13/24 4:55:53 PM ET
    $DIS
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G/A filed by Amgen Inc. (Amendment)

    SC 13G/A - AMGEN INC (0000318154) (Subject)

    1/30/24 11:35:57 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care